Vanderbilt Health study supports shift toward dynamic surveillance that extends monitoring for patients with specific demographic and histologic risk profiles.

The highly personalized treatment is currently approved for patients with advanced stages of melanoma whose tumors have grown despite immunotherapies and/or targeted therapies.

Appealing to patients for its noninvasive nature, it avoids many of the traditional drawbacks of surgeries that use incisions, including pain management. 

After moving to Nashville in 2011, Sallie and John chose Vanderbilt Health for their care because they valued being part of a teaching hospital.

The development of better biopsy approaches is driven by the fact that lung cancer kills more than 130,000 Americans annually, and survival depends on early diagnosis, which requires biopsy to be definitive.

Vanderbilt-Ingram was among the first in the nation to establish outpatient protocols for another personalized immunotherapy, CAR-T.

Study supports the potential benefits of screening patients for CHIP before they undergo cancer treatment so they can be more closely monitored for heart complications.